Related references
Note: Only part of the references are listed.Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S. Czuczman et al.
BLOOD (2012)
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
Jamie Honeychurch et al.
BLOOD (2012)
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
Myron S. Czuczman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres et al.
CLINICAL CANCER RESEARCH (2012)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2011)
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2011)
Radioimmunotherapy in follicular lymphoma
Tim Illidge et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
Margot Jak et al.
BLOOD (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
Sean H. Lim et al.
BLOOD (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H. Tilly et al.
ANNALS OF ONCOLOGY (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma
Lan Wu et al.
CANCER LETTERS (2010)
Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
Susumu Uchiyama et al.
CANCER SCIENCE (2010)
US Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery et al.
CLINICAL CANCER RESEARCH (2010)
Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Gillian M. Keating
DRUGS (2010)
Anti-CD20 monoclonal antibodies: historical and future perspectives
Sean H. Lim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
David M. Goldenberg et al.
BLOOD (2009)
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma
Bohua Li et al.
BLOOD (2009)
A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults
Pablo Bartolucci et al.
BLOOD (2009)
CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
Martha S. Hayden-Ledbetter et al.
CLINICAL CANCER RESEARCH (2009)
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
Nathalie A. Johnson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes
Federico Perosa et al.
JOURNAL OF IMMUNOLOGY (2009)
Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20
Jiamu Du et al.
MOLECULAR IMMUNOLOGY (2009)
Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
John D. Hainsworth et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers et al.
BLOOD (2008)
CD20 homo-oligomers physically associate with the B cell antigen receptor - Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins
Maria J. Polyak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2008)
Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide
Jiamu Du et al.
MOLECULAR IMMUNOLOGY (2008)
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Manzurul A. Sikder et al.
Current Hematologic Malignancy Reports (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Structural basis for recognition of CD20 by therapeutic antibody rituximab
Jiamu Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms
C Ferrara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor
F Perosa et al.
BLOOD (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Isolation and characterization of the B-cell marker CD20
JA Ernst et al.
BIOCHEMISTRY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
The radioisotope contributes significantly to the activity of radioimmunotherapy
TA Davis et al.
CLINICAL CANCER RESEARCH (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma:: long-term follow-up of a phase 1/2 study
LI Gordon et al.
BLOOD (2004)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia:: a phase II multicenter trial
GA Wiseman et al.
BLOOD (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure
MJ Polyak et al.
BLOOD (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
